Positive data reported from phase 1b/2a study of oral superagonist for epileptic seizures

A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, oral 5-HT2C receptor superagonist for seizures associated with developmental and epileptic encephalopathies.
According to a release from Longboard Pharmaceuticals, 52 participants in the phase 1b/2a PACIFIC study with a diagnosis of developmental and epileptic encephalopathies (DEE) who were treated with bexicaserin three times per day experienced a median decrease in countable motor seizure frequency from baseline of 53.3% compared with 20.8% for those receiving placebo.
Bexicaserin

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.